Ticker

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) today announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) and granted Priority Review for rusfertide. Rusfertide is an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of…

Citigroup Inc. grew its position in Protagonist Therapeutics, Inc. (NASDAQ: PTGX) by 95.7% in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 152,580 shares of the company's stock after buying an additional 74,629 shares during the quarter. Citigroup Inc. owned 0.24% of

(This release updates the release that posted earlier on February 25, 2026 to update the sub headlines.) NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2 U.S. regulatory decision for ICOTYDETM…

NDA for rusfertide submitted to the US Food and Drug Administration (FDA), with potential approval and launch this year Company expects to opt-out of the 50:50 profit and loss sharing arrangement for rusfertide with Takeda during a 90-day window expected to open in Q2 U.S. regulatory decision for ICOTYDETM (icotrokinra) anticipated in 2026 with  potential launch this year PN-881 Phase 1 completion expected by…

Hedge fund BVF sold 2,560,916 shares of PTGX in the fourth quarter. As a result, the quarter-end position value decreased by $170.12 million.